| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000015761 |
| Receipt No. | R000018341 |
| Official scientific title of the study | A Randomized, Double-blind, Placebo-controlled Study on the Anti-Obesity Effect of Food Containing Rosehip Extract |
| Date of disclosure of the study information | 2014/11/27 |
| Last modified on | 2019/03/05 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | A Randomized, Double-blind, Placebo-controlled Study on the Anti-Obesity Effect of Food Containing Rosehip Extract | |
| Title of the study (Brief title) | The Anti-Obesity Effect of Food Containing Rosehip Extract | |
| Region |
|
|
| Condition | |||
| Condition | No (Subjects whose BMI are 25 to 30) | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To examine the anti-obesity effect of food containing rosehip extract on body fat |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Abdominal fat area
Body fat percent |
| Key secondary outcomes | Weight
BMI Blood pressure Heart rate Waist circumference Hip circumference Skinfold thickness |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Tablet containing 100mg of rosehip extract, 1 per serving per day for 12 weeks | |
| Interventions/Control_2 | Tablet not containing rosehip extract, 1 per serving per day for 12 weeks | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | (1)Adult subjects whose BMI are 25 to 30
(2)Subjects giving written informed consent |
|||
| Key exclusion criteria | (1)Subjects who have allergic reaction to medicine.
(2)Subjects who smoke excessively and drink alcohol habitually, and whose eating habits are extremely irregular. (3)Subjects who has liver dysfunction or renal dysfunction. (4)Subjects who has history of surgery on gastrointestinal part such as gastrectomy, gastrointestinal suture, and intestinal resection. (5)Subjects who donated 400 mL of blood within 12 weeks before starting of administration, or who donated 200 mL of blood within 4 weeks or donated blood component within 2 weeks. (6)Midnight and irregular shift worker. (7)Subjects who are during pregnancy, nursing, and who plan to become pregnant within six months. (8)Subjects who are judged as unsuitable for the study by the investigator for other reason. |
|||
| Target sample size | 32 | |||
| Research contact person | |
| Name of lead principal investigator | Ikuo Fukuhara |
| Organization | Fukuhara clinic |
| Division name | Medical office |
| Address | 3-1-15 Shimamatsuhigashimachi, Eniwashi, Hokkaido |
| TEL | 0123-36-8029 |
| i-feniwa@gray.plala.or.jp | |
| Public contact | |
| Name of contact person | Akifumi Nagatomo |
| Organization | Morishita Jintan Co.,Ltd. |
| Division name | Research and Development Division |
| Address | Osaka Techno Center, 2-11-1, Tsudayamate, Hirakata, Osaka |
| TEL | 072-800-1044 |
| Homepage URL | |
| a-nagatomo@jintan.co.jp | |
| Sponsor | |
| Institute | Morishita Jintan Co.,Ltd. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Morishita Jintan Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | https://doi.org/10.2147/DMSO.S78623 |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018341 |